Evidence map›Paper›PMID 42212421›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026

Extensively drug-resistant (XDR)

Tajana Juzbašić, Tatjana Nemeth Blažić, Nilia Volarević, Ivana Bešlić, Daniela Glažar Ivče, Ivana Ferenčak, Dragan Jurić, Ljiljana Žmak, Dolores Peruč, Susanne Jacobsson and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tajana JuzbašićCroatian Institute of Public Health, Zagreb, Croatia.
Tatjana Nemeth BlažićCroatian Institute of Public Health, Zagreb, Croatia.
Nilia VolarevićTeaching Institute of Public Health of the Primorje-Gorski Kotar County, Rijeka, Croatia.
Ivana BešlićCroatian Institute of Public Health, Zagreb, Croatia.
Daniela Glažar IvčeTeaching Institute of Public Health of the Primorje-Gorski Kotar County, Rijeka, Croatia.
Ivana FerenčakCroatian Institute of Public Health, Zagreb, Croatia.
Dragan JurićCroatian Institute of Public Health, Zagreb, Croatia.
Ljiljana ŽmakCroatian Institute of Public Health, Zagreb, Croatia.
Dolores PeručTeaching Institute of Public Health of the Primorje-Gorski Kotar County, Rijeka, Croatia.
Susanne JacobssonWHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Daniel GolparianWHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Ivana BožičevićWHO Collaborating Centre for HIV Strategic Information, Andrija Štampar School of Public Health, School of Medicine, University of Zagreb, Zagreb, Croatia.
Iskra Alexandra NolaAndrija Štampar School of Public Health, School of Medicine, University of Zagreb, Zagreb, Croatia.
Magnus UnemoWHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In early 2026 in Croatia, a male heterosexual patient of Croatian origin was diagnosed with extensively drug-resistant (XDR) gonorrhoea after unprotected vaginal intercourse with a Croatian female. The

Indexed as

Anti-Bacterial AgentsCeftriaxoneDrug Resistance, Multiple, BacterialGonorrheaNeisseria gonorrhoeaeAdministration, IntravenousAzithromycinCroatiaFemaleHumansMaleMicrobial Sensitivity TestsMultilocus Sequence TypingRNA, Ribosomal, 23STreatment OutcomeAnti-Bacterial AgentsAzithromycinCeftriaxoneRNA, Ribosomal, 23Sceftriaxone resistanceCroatiaextensively drug-resistant (XDR)gonorrhoeahigh-level azithromycin resistanceNeisseria gonorrhoeae

Identifiers

PMID42212421
PMCPMC13235652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.